Abstract:Assessment and management of children with growth failure has improved greatly over recent years. However, there remains a strong potential for further improvements by using novel digital techniques. A panel of experts discussed developments in digitalization of a number of important tools used by pediatric endocrinologists at the third 360° European Meeting on Growth and Endocrine Disorders, funded by Merck KGaA, Germany, and this review is based on those discussions. It was reported that electronic monitoring and new algorithms have been devised that are providing more sensitive referral for short stature. In addition, computer programs have improved ways in which diagnoses are coded for use by various groups including healthcare providers and government health systems. Innovative cranial imaging techniques have been devised that are considered safer than using gadolinium contrast agents and are also more sensitive and accurate. Deep-learning neural networks are changing the way that bone age and bone health are assessed, which are more objective than standard methodologies. Models for prediction of growth response to growth hormone (GH) treatment are being improved by applying novel artificial intelligence methods that can identify non-linear and linear factors that relate to response, providing more accurate predictions. Determination and interpretation of insulin-like growth factor-1 (IGF-1) levels are becoming more standardized and consistent, for evaluation across different patient groups, and computer-learning models indicate that baseline IGF-1 standard deviation score is among the most important indicators of GH therapy response. While physicians involved in child growth and treatment of disorders resulting in growth failure need to be aware of, and keep abreast of, these latest developments, treatment decisions and management should continue to be based on clinical decisions. New digital technologies and advancements in the field should be aimed at improving clinical decisions, making greater standardization of assessment and facilitating patient-centered approaches.

Novel therapies for growth disorders

Progress on growth promoting therapies other than growth hormone.

Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review

Two years in growth hormone 2017-18

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age.

New treatments for children with achondroplasia

C-Type Natriuretic Peptide Analogs: Current and Future Therapeutic Applications

Growth Hormone Treatment for Non-GHD Disorders: Excitement Tempered by Biology

Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature

Approach to the Peripubertal Patient With Short Stature

Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review

Long-acting recombinant human growth hormone in the treatment of pediatric growth hormone deficiency, how far have we got?

Important Tools for Use by Pediatric Endocrinologists in the Assessment of Short Stature

The role of recombinant insulin-like growth factor I in the treatment of the short child

Boosting The Late Blooming Male: Use of growth promoting agents in the athlete with constitutional delay of growth and puberty

Recombinant human insulin-like growth factor-I therapy for children with growth disorders

The current state of long-acting growth hormone preparations for growth hormone therapy

Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency

Long-acting growth hormone in the management of GHD in France

Update on the use of long-acting growth hormone in children